'; Mayo Clinic Q&A podcast: Advancing research, challenging cancer – Dr Fundile Nyati

Mayo Clinic Q&A podcast: Advancing research, challenging cancer

Mayo Clinic Q&A podcast: Advancing research, challenging cancer
multi pipette research of cancer stem cells

Almost half of all people in the U.S. are at risk of developing some form of cancer in their lifetime, according to the National Cancer Institute. For women, it’s often breast cancer. For men, it’s prostate cancer. For both populations lung cancer and colorectal cancer are common.

Dr. Paul Limburg, a Mayo Clinic gastroenterologist and cancer researcher with the Mayo Clinic Cancer Center, says you can lower your risk of cancer by knowing your personal and family medical histories, as well as developing a healthy lifestyle that includes exercise.

He also says researchers are studying healthy people to see whether medications or supplements could help modify cancer risk.

“It’s called chemo prevention,” says Dr. Limburg. “It goes back to the biologic development of cancers, precancers. For example, inflammation seems to be an important contributor to the development of cancer, so could anti-inflammation medications help reduce cancer risk?”

In this Mayo Clinic Q&A podcast, Dr. Limburg talks more about cancer research at Mayo, including new technologies and the possibility of a single blood test to screen for multiple cancers.

Learn more about Mayo Clinic Cancer Center – Research and Clinical Trials.

___________________________________

Watch: Dr. Limburg discusses cancer prevention, detection and research.

___________________________________

For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was either recorded prior to COVID-19 or recorded in a nonpatient care area where social distancing and other safety protocols were followed.

Tell us about your thoughtsWrite message

Your email address will not be published. Required fields are marked *

Back to Top
Close Zoom
This is not allowed.